Proactive Investors - Run By Investors For Investors

Rhinomed Limited to advance distribution of snoring product

Rhinomed Limited to advance distribution of snoring product

Rhinomed Limited (ASX:RNO) has been granted an ASX trading halt in relation to the appointment of an Australian Pharmacy Distribution group for its Mute over-the-counter snoring product.
The halt will last until the earlier of the announcement being made or the start of trade on Wednesday, 1st April 2015.

Independent user trial results (conducted November 2014) confirmed the efficacy of Mute with 75% of respondents reported a reduction in snoring.

Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.

View full RNO profile View Profile

Rhinomed Ltd Timeline

September 15 2015

Related Articles

man with erectile dysfunction
June 17 2019
Headline results from the trial of MED2005 are due before the end of 2019, while Futura is also confident of hearing back from UK regulators about its pain relief gel later in the year
Callitas CEO James Thompson
July 20 2018
CannaStrips will generate near-term revenue, while the company’s blue-sky pharmaceutical assets and orphan drug are solid, long-term plays
June 11 2019
Oncimmune is a specialist in the field of immunodiagnostics
Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use